Oral Semaglutide Fails to Slow Cognitive Decline in Large Alzheimer's Trials
Summary
Two large Phase 3 clinical trials (evoke and evoke+) revealed that oral semaglutide does not slow the progression of early-stage Alzheimer's disease. Involving 3,808 participants aged 55-85 with mild cognitive impairment or dementia, the studies compared a daily 14 mg dose of semaglutide against a placebo. After two years, researchers observed no significant difference in cognitive and functional decline between the groups. Due to this lack of efficacy, the trials were discontinued. The drug's safety profile remained consistent with its established use for diabetes and weight loss.
Why This Is Interesting
This result is important because it challenges the growing hope that GLP-1 agonists, a class of drugs highly effective for diabetes and weight loss, could be repurposed to treat neurodegenerative diseases. Previous animal studies and observational data had suggested a potential link between these drugs and a reduced risk of dementia. These two large, well-designed trials provide strong evidence that, at least for oral semaglutide in this specific population, that promise did not materialize. For the public, this is a crucial reminder that promising early signals must be confirmed in rigorous human trials. It helps manage expectations and redirects research efforts toward other potential pathways for treating this devastating disease.
Published in The Lancet
"Oral Semaglutide Fails to Slow Cognitive Decline in Large Alzheimer's Trials." *The Lancet*, 23 Mar. 2026, pubmed.ncbi.nlm.nih.gov/41865758/.